These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6308717

  • 1. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E, Kalivas PW, Lewis MH, Prange AJ, Breese GR.
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [Abstract] [Full Text] [Related]

  • 2. Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats.
    Ladurelle N, Keller G, Roques BP, Daugé V.
    Brain Res; 1993 Nov 19; 628(1-2):254-62. PubMed ID: 8313154
    [Abstract] [Full Text] [Related]

  • 3. Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats.
    Weiss F, Tanzer DJ, Ettenberg A.
    Pharmacol Biochem Behav; 1988 Jun 19; 30(2):309-17. PubMed ID: 3174761
    [Abstract] [Full Text] [Related]

  • 4. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN.
    J Neurosci; 1992 Sep 19; 12(9):3380-91. PubMed ID: 1527584
    [Abstract] [Full Text] [Related]

  • 5. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G, Itoh S, Hsiao S.
    Peptides; 1985 Sep 19; 6(1):91-6. PubMed ID: 3991366
    [Abstract] [Full Text] [Related]

  • 6. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry.
    Reum T, Fink H, Marsden CA, Morgenstern R.
    Neuropeptides; 1998 Apr 19; 32(2):161-6. PubMed ID: 9639255
    [Abstract] [Full Text] [Related]

  • 7. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH.
    Prog Clin Biol Res; 1985 Apr 19; 192():131-8. PubMed ID: 4080706
    [Abstract] [Full Text] [Related]

  • 8. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN, Stivers JA, Blumstein LK, Paul SM.
    J Neurosci; 1985 Aug 19; 5(8):1972-83. PubMed ID: 4040554
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN.
    Synapse; 1989 Aug 19; 3(4):346-55. PubMed ID: 2740993
    [Abstract] [Full Text] [Related]

  • 12. NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.
    Nissbrandt H, Engberg G, Wikström H, Magnusson T, Carlsson A.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Aug 19; 338(2):148-61. PubMed ID: 3141816
    [Abstract] [Full Text] [Related]

  • 13. Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences.
    Pettit HO, Mueller K.
    Psychopharmacology (Berl); 1989 Aug 19; 99(3):423-6. PubMed ID: 2594910
    [Abstract] [Full Text] [Related]

  • 14. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat.
    Debonnel G, de Montigny C.
    Synapse; 1988 Aug 19; 2(5):537-45. PubMed ID: 2903570
    [Abstract] [Full Text] [Related]

  • 15. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission.
    Ericson E, Ahlenius S.
    Brain Res; 1999 Mar 20; 822(1-2):200-9. PubMed ID: 10082897
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F, Ettenberg A, Koob GF.
    Psychopharmacology (Berl); 1989 Mar 20; 99(3):409-15. PubMed ID: 2574480
    [Abstract] [Full Text] [Related]

  • 18. [The effect of cholecystokinin octapeptide on ethanol-induced changes in motor activity and in dopamine metabolism in the nucleus accumbens of the rat brain].
    Medvedeva OF, Sudakova SK, Anokhina IP, Kianmaa K.
    Eksp Klin Farmakol; 1996 Mar 20; 59(6):44-7. PubMed ID: 9181874
    [Abstract] [Full Text] [Related]

  • 19. Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8).
    Murphy RB, Schuster DI.
    Peptides; 1982 Mar 20; 3(3):539-43. PubMed ID: 6289286
    [Abstract] [Full Text] [Related]

  • 20. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN, Hommer DW, Skirboll LR.
    Brain Res; 1985 Jun 03; 335(2):337-41. PubMed ID: 4005562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.